The long-running legal dispute between Amgen and Sanofi/Regeneron on two key patents covering the use of PCSK9 inhibitors to lower cholesterol has come to an end, with Sanofi emerging as the victor.

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol. The new ...

血脂异常作为心血管疾病的重要危险因素，日益受到医药界和公众的广泛关注。近日针对血脂异常，一款新一代超长效PCSK9单抗-瑞卡西单抗在我国正式获批。该创新药有何特点和优势？日常生活中我们应该如何有效管理血脂？对此，新华网《新药来了》特别邀请 ...

CRISPR-Cas systems have been exploited for targeted genome editing. Applying the CRISPR-Cas9 system to edit high GC content genomes has been challenging due to its high off-target activity.